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Abstract
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, 
and the second leading cause of cancer-related mortality worldwide with a very poor 
5-year survival. Treatment for HCC includes surgery, liver-directed therapies and sys-
temic therapies. Until 2008, no effective systemic therapy was available for advanced 
HCC. Sorafenib is the first drug to show improvement in overall survival among patients 
with advanced HCC in comparison to placebo, and it is approved by U.S. Food and 
Drug Administration (FDA) as a first-line treatment of advanced HCC. After sorafenib 
approval, several targeted and immune therapies were tested and showed efficacy in 
advanced HCC. Lenvatinib has been shown to be non-inferior to sorafenib as first-line 
treatment. Both nivolumab and regorafenib showed improvement in overall survival 
among patients with advanced HCC as a second line treatment after progression on 
sorafenib, and both are FDA approved for this indication. There is a limited role for cyto-
toxic agents in the treatment of advanced HCC.
Keywords: hepatocellular, carcinoma, HCC, kinase, inhibitors, TKI, VEGFR, sorafenib, 
lenvatinib, regorafenib, immunotherapy, PD-L1, nivolumab
1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. HCC is the 
second leading cause of cancer-related mortality worldwide with a very poor 5-year survival. 
The incidence of HCC has been increasing over the past decades [1]. Risk factors for HCC 
include hepatitis B and C infection, alcohol use, non-alcoholic steatohepatitis, and aflatoxin. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Treatment approaches for HCC depend on the stage and the hepatic function, and includes 
surgical therapies (liver transplantation, resection, and ablation) and nonsurgical therapies, 
which may be liver-directed (percutaneous ethanol injection, radiofrequency ablation, trans-
arterial embolization, external beam radiation therapy) or systemic therapies.
Until 2008, there was no effective systemic therapy for advanced HCC. Cytotoxic chemo-
therapy has not been used routinely as of low efficacy and poor functional status for patients 
with advanced HCC, who often have cirrhosis. Since the advent of sorafenib in 2008, there has 
been a surge of several targeted and immune therapies with various degree of effectiveness. 
In this chapter, systemic therapies for advanced HCC will be reviewed. Those include oral 




Sorafenib is a multi-kinase inhibitor of vascular endothelial growth factor receptors (VEGFR), 
platelet-derived growth factor receptor (PDGFR) and Raf family kinases [2]. Sorafenib has 
shown to improve overall survival in comparison to placebo in advanced HCC, and it was the 
first drug to get Food and Drug Administration (FDA) approval as a first-line treatment for 
Child-Pugh score-A HCC. In the multicenter European SHARP trial, 602 inoperable HCC and 
Child-Turcotte-Pugh-A cirrhosis patients, were assigned to sorafenib (400 mg twice daily) or 
placebo [3]. The primary endpoint of the trial was overall survival, which was significantly 
longer in the sorafenib-treated group (10.7 vs. 7.9 months). Time to radiologic progression 
was also longer (5.5 vs. 2.8 months). Objective response rates were low at 2%.
Sorafenib was well tolerated in this trial. Diarrhea and hand-foot skin reaction were the only 
grade 3 or 4 adverse effects that occurred significantly more often in the treated group; (8 vs. 
2%) and (8 vs. <1%) respectively. There were no differences in liver dysfunction or bleeding.
An exploratory analysis of SHARP trial showed that hepatitis C related HCC has the highest 
median overall survival advantage of 6.6 months (14 vs. 7.4 months). This is in comparison to 
3.6 months (9.7 vs. 6.1 months) in those with HBV related cirrhosis and 2.3 months (10.3 vs. 
8 months) in those with alcohol-related liver disease [4].
Hepatitis B virus is more prevalent in the Asian patients than in the Western population. 
Sorafenib was tested as a first-line treatment in Asian patients in a placebo-controlled phase 
III trial in which 226 patients with Child-Turcotte-Pugh A cirrhosis received sorafenib 400 mg 
twice daily or placebo [5]. Patients receiving sorafenib had significantly higher median overall 
survival (6.5 vs. 4.2 months). Grade 3 or 4 side effects were similar to SHARP trial.
Based on the results of SHARP trial, the FDA approved sorafenib monotherapy as first-line 
therapy for unresectable HCC.
It is worth mentioning that the patients enrolled in the above trials had mostly Child-Turcotte-
Pugh A cirrhosis. This is not representative of the real practice where a significant number of 
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patients have more advanced cirrhosis. FDA approval of sorafenib for HCC did not particu-
larly specify the underlying cirrhosis state. Data regarding safety and efficacy of sorafenib in 
patients with Child-Turcotte-Pugh B or C cirrhosis are limited, and suggest that patients have 
poorer overall survival and overall worse side effect profile in comparison to patients with 
Child-Turcotte-Pugh A. Advanced progressive cirrhosis rather than sorafenib itself might be 
an explanation for such differences [6, 7].
Sorafenib is associated with several side effects such as hypertension, cardiotoxicity, arterial 
thromboembolism, bleeding, renal toxicity, hand-foot skin reaction and others. Sorafenib has 
been associated with potentially fatal liver toxicity. Liver function tests should regularly be 
monitored during treatment.
2.1.1. Combining sorafenib with doxorubicin
In a phase II trial, the combination of six cycles of doxorubicin with sorafenib 400 mg twice 
daily was compared to sorafenib and placebo [8]. Combination therapy was associated sig-
nificantly longer median time to tumor progression (6.4 vs. 2.8 months) and median overall 
survival duration (13.7 vs. 6.5 months). The side effect profile was not significantly worse with 
combined therapy. However those results were not reproduced in the randomized phase III 
trial, Cancer and Leukemia Group B [CALGB] trial 80,802 [9]. The study was stopped early 
by the data monitoring safety board after a planned interim analysis suggested futility for 
the combination. In a preliminary report presented at the 2016 American Society of Clinical 
Oncology (ASCO) Gastrointestinal Cancers Symposium, median overall survival was not sig-
nificantly better for the combination (9.3 vs. 10.5 months), nor was median progression-free 
survival (3.6 vs. 3.2 months), but toxicity was worse.
2.2. Lenvatinib
Lenvatinib is a multi-kinase inhibitor of VEGFRs, fibroblast growth factor receptors (FGFR), 
(PDGFR), c-Kit, and the RET proto-oncogene [10].
A randomized noninferiority trial, the REFLECT study, compared lenvatinib (12 mg once 
daily for body weight ≥60 kg, 8 mg daily for <60 kg) with sorafenib (400 mg daily for all 
patients) in 954 patients with unresectable HCC and no prior systemic therapy (99% Child-
Turcotte-Pugh A) [11]. The predefined noninferiority margin (primary endpoint overall 
survival) was 1.08. Lenvatinib was noninferior to sorafenib (median overall survival 13.6 vs. 
12.3 months, hazard ratio 0.92, 95% CI 0.79–1.06), the objective response rate was higher (24 
vs. 9%), and median time to progression was longer (7.4 vs. 3.7 months, hazard ratio 0.66, 
95% CI 0.57–0.77). Lenvatinib leads to higher grade 3 or 4 hypertension (23 vs. 14%), while 
sorafenib was associated with higher hand-foot skin reaction (11 vs. 3%).
Lenvatinib was approved in Japan in March 2018 for unresectable HCC. Lenvatinib is not 
approved by FDA yet.
Both sorafenib and lenvatinib can be used in the first-line treatment of advanced HCC. There 
are no data on second-line treatment after lenvatinib and whether lenvatinib is effective as a 
second line after sorafenib.




Regorafenib is an antiangiogenic (including VEGFR-1, VEGFR-2, and VEGFR-3), anti-stromal, 
and an oncogenic tyrosine kinase inhibitor that is structurally similar to sorafenib [12].
In the randomized RESORCE trial, 573 patients who received sorafenib for at least 20 days at 
a dose of at least 400 mg daily and who had radiologic progression were randomly assigned 
to regorafenib (160 mg once daily for 3 weeks on and 1 week off) or placebo [13]. Regorafenib 
was associated with significantly higher median OS (10.6 vs. 7.8 months, hazard ratio for 
death 0.63) and disease control (objective response plus stable disease; 65 vs. 36%).
Treatment was relatively well tolerated; grade 3 or 4 hypertension, hand-foot skin disease 
and fatigue were more frequent with regorafenib. Sixty-eight percent of patients treated with 
regorafenib required dose modification for adverse events compared with 31% of the placebo 
group.
In April 2017, the FDA expanded the indications for regorafenib to include patients with HCC 
who had been previously treated with sorafenib.
Regorafenib is an alternative to nivolumab for second-line HCC treatment. There are no trials 
comparing regorafenib with nivolumab in this setting.
2.4. Cabozantinib
Cabozantinib is another inhibitor of several receptor tyrosine kinases, including the hepa-
tocyte growth factor/c-MET and VEGFR [14]. Efficacy in patients with previously treated 
advanced HCC was shown in the placebo-controlled phase III CELESTIAL trial [15]. In a 
preliminary report, in the group of patients receiving second- or third-line treatment, median 
overall survival was significantly better with cabozantinib (10.2 vs. 8.0 months), and the dif-
ference was more pronounced when the analysis was limited to patients whose only prior 
therapy was sorafenib (median overall survival 11.3 vs. 7.2 months). The most common grade 
3 or 4 adverse events with cabozantinib were palmar-plantar erythrodysesthesia (17 vs. 0 in 
the placebo group), hypertension (16 vs. 0%), increased aspartate aminotransferase (12 vs. 
7%), fatigue (10 vs. 4%), and diarrhea (10 vs. 2%).
2.5. Axitinib
Axitinib is a selective kinase inhibitor that inhibits VEGFR. Axitinib was not superior to best 
supportive care alone in a randomized phase II trial comparing best supportive care plus 
axitinib (starting dose 5 mg twice daily) with placebo in 202 patients with advanced HCC who 
progressed on or were intolerant of one prior antiangiogenic therapy [16]. The difference in 
median overall survival (the primary endpoint), was not statistically significant (12.7 vs. 9.7).
2.6. Sunitinib
Sunitinib is another orally active multi-kinase inhibitor that targets a variety of tyrosine 
kinases in addition to VEGFR, including PDGFRs, KIT, RET, and FMS-like tyrosine kinase 3 
(FLT3) [17].
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Sunitinib was significantly inferior to sorafenib in a phase III trial that directly compared both 
drugs in 1073 previously untreated patients with advanced HCC [18]. The trial was closed 
prematurely when an interim analysis revealed that patients receiving sunitinib had signifi-
cantly worse survival (median 7.9 vs. 10.2 months) and more frequent and severe treatment-
related toxicity.
3. Antiangiogenic monoclonal antibodies
3.1. Bevacizumab
Bevacizumab is a monoclonal antibody directed against VEGFR that has some activity in 
advanced HCC. Efficacy was shown in a trial in which 46 patients with advanced nonmeta-
static HCC received single-agent bevacizumab at a dose of either 5 or 10 mg/kg once every 
other week [19]. An objective response was documented in six (13%, one complete), and the 
median progression-free survival was 6.9 months. The most common grade 3 or 4 toxicities 
were hypertension (15%), thrombosis (6%), and major bleeding (11%).
Bevacizumab is also active in combination with capecitabine, with or without oxaliplatin 
[20, 21], and gemcitabine combined with oxaliplatin (GEMOX) [22]. Whether any of those 
combination regimens are better than bevacizumab alone is not clear and will require ran-
domized trials.
3.2. Ramucirumab
Ramucirumab is a recombinant monoclonal antibody that binds to VEGFR-2. The REACH 
trial failed to show a significant survival advantage relative to placebo (median overall sur-
vival 9.2 vs. 7.6 months) in patients with advanced HCC who progressed on sorafenib [23]. An 
unplanned group analysis suggested a possible survival benefit in patients with a high initial 
level of alpha-fetoprotein (AFP) above 400 ng/mL) at diagnosis. A follow-up phase III trial in 
patients with AFP-elevated HCC is ongoing.
4. Immunotherapeutic approaches
4.1. Introduction
Immune-based approaches that focus on vaccination strategies, cytokines or non-specific T 
cell activation have been tested for many years in HCC without promising result. However, 
the recent advancement in immune-oncology with the FDA approval of many immune 
checkpoint inhibitors, sparked a great interest in the immune-based treatment approaches for 
patients with HCC. The strategy of adopting an immunocentric approach to HCC treatment 
may be potentially more efficacious and less toxic. Interestingly, what makes the immuno-
therapy appealing in liver cancer is that HCC is a high immunogenic cancer, due to high blood 
flow with unique vast tumor antigen repertoire because of mutations and aberrant expression 
profiles [24]. On the other hand, there is an inherently immunosuppressive microenvironment 
Biologic and Immunotherapy Developments in Advanced Hepatocellular Carcinoma
http://dx.doi.org/10.5772/intechopen.79872
163
of the liver; “Tolerogenic Liver”; that helps evade the immune response. The liver’s pathway 
to immune tolerance is multifactorial. T-cells are stimulated through a dual signaling pathway 
that requires the interaction of T cell receptors (TCR) with major histocompatibility complex 
(MHC)/peptide complexes on antigen presenting cells (APCs) and expression of co-stimu-
latory molecules on T cells and APCs. Down-regulation of MHC class I molecules on tumor 
cells induces impairment of tumor antigen processing and presentation [25]. In addition, a 
reduced expression of co-stimulatory molecules, such as B7-1 and B7-2, in HCC leads to T 
cell anergy [26]. Programmed cell death protein-1 (PD-1) overexpression in tumors promotes 
immune evasion and tumor growth by suppressing T-cell response [27]. PD-L1 is not the only 
immunosuppressive factor in the tumor microenvironment. HCC immune evasion can also 
be achieved through overexpression of MHC class II molecules in tumor cells, which leads to 
CD4+ T cell anergy in the absence of co-stimulatory molecules (CMs) on T cells and APCs. A 
better understanding of the antigenic profile of HCC and tumor microenvironment has helped 
to develop a refined immunotherapeutic strategies in treatment of HCC [28].
4.2. Indirect immunological strategies
4.2.1. Checkpoint inhibitors
Checkpoint Inhibitors play critical roles in cancer immunology. Blockading the PD-1/PD-L1 
pathway could modulate the tumor microenvironment, reactive T-cell and prime the endog-
enous antitumor immune responses. Treatment with checkpoints inhibitors have shown 
benefits in clinical trials of HCC. Common immune checkpoint proteins include cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4), PD-1, programmed cell death ligand one (PD-L1), 
lymphocyte activation gene three protein (LAG-3), B and T lymphocyte attenuator (BTLA), 
T-cell immunoglobulin and mucin-domain-containing (TIM-3), VISTA and OX40 [29, 30].
4.2.1.1. CTLA-4 inhibitors
CTLA-4 is constitutively expressed in activated T cells and NK cells [31]. CTLA-4 inhibitors 
prevent the binding of CTLA-4 to B7-1 and B7-2, thereby actively encourage the activation 
of T cells. CTLA-4 was the first checkpoint studied in HCC. Tremelimumab, an anti-CTLA-4 
monoclonal antibody, was tested in a phase II study in a 21 patients with advanced HCC and 
hepatitis C. The disease control rate was (76.4%), median OS and PFS were 7.5 and 6.4 months 
respectively. Moreover, viral loads of HCC were significantly reduced. Although a short-
lived remarkable rise in serum transaminases was observed after the first dose, no patients 
experienced immune-related adverse events or serious hepatotoxicity [32]. In another non-
comparative clinical trial involving patients with advanced HCC, a combination therapy of 
tremelimumab and radiofrequency ablation increased the number of intratumoral CD8+ T 
cells and reduced HCV viral loads [33].
4.2.1.2. PD-1 inhibitors
The PD-L1/PD-1 pathway is another mechanism of tumor-induced immune tolerance. PD-1 
expression on effecter phase CD8+ T cells is increased in patients with HCC compared to 
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no HCC cirrhotic patients [34]. Moreover, there is frequent and early disease progression in 
patients with HCC with higher numbers of tumor-infiltrating and circulating PD-1 + CD8+ 
T cells post hepatic resection [35]. Therefore, a supporting great rationale exists for using 
PD-1 and PD-L-1 blocking antibodies against HCC. Some PD-1 inhibitors, such as nivolumab, 
pembrolizumab, and pidilizumab, have been investigated for cancer treatment.
The CheckMate-040 phase I/II trial studied the safety and antitumor effect of nivolumab in 48 
patients with advanced HCC [36]. The target population included patients with intermedi-
ate or advanced HCC and preserved liver function (Child-Turcotte-Pugh-A cirrhosis) who 
were candidates for systemic therapy and had progressed or were intolerant to sorafenib. In 
the escalation and expansion cohorts, objective tumor responses occurred in 15 and 20% of 
patients, respectively. There were durable responses that lasted for a median of 17 months. An 
additional 45% of patients had a stable disease associated with durability, lasting 6 months 
at minimum. Those responses were consistent across the different HCC risks, and both in 
sorafenib-naïve and sorafenib-exposed patients.
Overall, frequencies of grade 3/4 treatment-related AEs were 20%. Only 3% of patients discon-
tinued nivolumab because of treatment-related adverse events, while no treatment-related 
deaths occurred. Elevated transaminases was the most frequent laboratory alteration (20%). 
However, only 5% of the patients had grade 3 or higher. Immune-related hepatitis requiring 
steroid therapy. CheckMate-040 showed that nivolumab might be effective with acceptable 
toxicity in HCC, regardless of hepatitis status. On September 22, 2017, and based on the out-
come of CheckMate-040 study, the FDA granted accelerated approval to nivolumab for the 
treatment of hepatocellular carcinoma (HCC) as second-line therapy in patients who have 
been previously treated with sorafenib.
CheckMate-459 is an ongoing phase III study, (NCT02576509) that randomizes patients with 
advanced HCC to either nivolumab or sorafenib in the first-line setting [37].
The efficacy and safety of pembrolizumab in HCC has been investigated. The phase I/II study 
KEYNOTE-224 tested pembrolizumab in 104 patients with advanced HCC who progressed 
on sorafenib. The overall response rate was 16.3%. Durable response was seen with 94% of 
responders were estimated to have a response duration of 6 months or longer. The median 
PFS was 4.8 months, and the median OS was not been reached. The safety profile was gener-
ally comparable to that established for pembrolizumab monotherapy in other indications, 
and no viral flares were seen [38].
4.2.2. Oncolytic immunotherapy
Targeting tumor vasculature by oncolytic viruses (OVs) is an attractive strategy that offers sev-
eral advantages. Oncolytic viruses are wild-type or engineered viruses that selectively target 
and replicate in cancer cells and cause lysis without harming normal tissues [39]. The underly-
ing mechanism of the antitumor activity for oncolytic viruses involves direct killing of tumor 
cells by expanding in the cells and causing cell lysis. Different from normal cell, viruses can 
expand in cancer cells considerably due to the impairment of the tumor’s defense mechanisms 
against viral infection. [40–43]. In addition,, OVs can initiate antitumor immune response by 
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triggering key signals through oncolysis to dendritic cells (DCs) and other antigen-presenting 
cells (APCs) [44]. OVs have some advantages over other treatment modalities, those include: 
the low probability of generating resistance as OVs often target multiple oncogenic pathways; 
OVs replicate in a tumor-selective fashion with minimal systemic toxicities; and virus dose 
in the tumor increases over time due to in situ virus amplification, as opposed to classical 
drug pharmacokinetics that decreases with time [45]. The efficacy of an evolutionary cancer-
favoring engineered vaccinia virus (CVV) was investigated in an animal model of metastatic 
HCC. In this animal study, the subjects were randomized into sorafenib, CVV, or sorafenib 
with CVV. Metastatic regions were interestingly rare in the CVV-treated groups (i.e., CVV or 
sorafenib with CVV) whereas metastatic regions existed in the sorafenib-treated group [46].
JX-594 is a thymidine kinase gene-inactivated oncolytic vaccinia virus engineered for the 
expression of transgenes encoding human granulocyte-macrophage-colony-stimulating fac-
tor (GM-CSF) and β-galactosidase, which increases antitumor immune responses [39, 47–49] 
This virus is safe in humans and extremely toxic to cancer cells.
Oncolytic viruses have produced enough therapeutic efficacy with great optimism in the 
future trials. Although the initial concerns of clinical investigators were for safety like a risk 
of viral infection or introduce oncogenic mutation, these have proven not to be a significant 
issue in these trials.
4.2.3. HCC vaccines
Cancer vaccination is performed by utilizing antigenic substances to stimulate tumor-specific 
immune responses that can remove cancer cells and prevent recurrences. HCC vaccines 
include cancer cells, antigen peptides, DCs, and DNA-based.
4.2.3.1. Antigen peptide vaccines
Peptide-based tumor-associated antigens (TAAs), such as alpha-fetoprotein (AFP), GPC3, 
SSX-2, NY-ESO-1, human telomerase reverse transcriptase (hTERT), HCA587, and melanoma 
antigen gene-A (MAGE-A), are excellent vaccine targets for the treatment of HCC [50].
AFP which normally originates from embryonic liver cells, can be overexpressed on HCC cell 
surfaces. However, immune responses to AFP are limited due to acquired immune tolerance 
during the development of the immune system. To overcome this tolerance, a research group 
investigated the use of a recombinant rat AFP to induce cross-reactions between xenografts 
and endogenous molecules in animals and observed modest cellular and humoral immune 
responses [51]. In a phase II trial of GPC3-derived peptide vaccine for HCC, 25 patients 
received 10 vaccinations over 1 year after surgery. The recurrence rate in patients who under-
went both surgery and vaccination was significantly lower than the rate in 21 patients who 
underwent surgery only (24% vs. 48 and 52.4% vs. 61.9% at 1 and 2 years, p = 0 047 and 0.387, 
respectively), demonstrating the efficacy of the GPC3-derived vaccine [52].
4.2.3.2. Dendritic cell (DC) vaccines
DCs, were found to be the most powerful APCs in the body’s immune system, and capable of 
stimulating naïve T cells and driving primary immune responses. A phase I/IIa comparative 
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study with 30 patients with advanced HCC stratified into mature autologous DCs pulsed, and 
other control group received supportive treatment. The result demonstrated an improvement in 
overall survival with two patients (13.3%) partial radiological response was observed, and nine 
patients (60%) has stable disease. The study concludes using tumor antigen-pulsed DCs vaccine 
can be effective adjuvant therapy with other treatment modalities of HCC or palliative treat-
ment option in advanced HCC where other treatment options are not applicable [53]. In addi-
tion, the safety and tolerance of DC vaccines have been confirmed in patients with HCC [54].
4.3. Direct immunological strategy
4.3.1. Adoptive cell therapy
Adoptive cell therapy (ACT) is an immunotherapeutic approach that attacks cancer cells using 
genetically engineered patients’ lymphocytes. It functions by stimulating or loading autologous 
lymphocytes with cytokines or tumor antigens, cultivating them ex vivo and then re-infusing 
them into the patient [55–57]. Adoptive immunotherapy for HCC includes cytokine-induced 
killer (CIK) cells, tumor-infiltrating lymphocytes (TILs), natural killer (NK) cells, and chimeric 
antigen receptor (CAR) T cells. The effectiveness and safety of ACT in patients with HCC have 
been studied in many experiments, which paved the road for its clinical implication.
4.3.1.1. Cytokine induced killer cells (CIK)
CIK cells are a heterogeneous MHC independent cell population which are able to both rec-
ognize tumor antigens and kill cancer cells directly [58, 59]. In a phase III study of adjuvant 
CIK therapy after radical resection for HCC, patients were randomized to receive four cycles 
of CIK therapy or no treatment. The median time to recurrence (TTR) was 13.6 months in the 
CIK group and 7.8 months in the control group (p = 0.01), All adverse events were grade 1 or 2. 
There were no significant differences in incidence between the two groups, indicating the safety 
and efficacy with respect to prolonging TTR of CIK therapy in patients with HCC. However, 
there were no statistically significant differences between the groups in disease-free survival 
(DFS) and overall survival (OS) [60]. In addition, a meta-analysis of 693 patients with HCC 
demonstrated that a combination of dendritic cell- (DC-) CIK cells and TACE improves 1-and 
2-year OS, overall response rate (ORR), disease control rate (DCR), and the quality of life [61].
4.3.1.2. Tumor infiltrating lymphocytes (TILs)
TILs are autologous tumor-infiltrating lymphocytes (TIL), which are derived from tumor 
tissues and are cultured and induced using IL-2 and anti-CD3 antibodies ex vivo [62–64]. 
Reinfusion of autologous TILs, which possess tumor-specific immunity, may target multiple 
tumor antigens. Low toxicity of autologous TILs was verified in a phase I study involving 
patients with HCC, suggesting a novel treatment option [65]. To date, TILs have not been well 
characterized, mainly due to difficulties in purifying and expanding them.
4.3.1.3. Natural killer cells (NKCs)
NK cells are component of innate immune system and can directly kill tumor cells and 
infected cells without preliminary sensitization or MHC restriction [66]. However, they lack 
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the ability to target tumor cells and can injure normal liver tissues. In a previous series of 
experiments, the cytotoxicity of NK cells against HCC cells was enhanced by first generating 
a new hepatoma cell line, K562-mb15-41BBL, which achieved a more efficient stimulation of 
NK cells in vitro [67]. Furthermore, HCC cells exposed to 5 μmol/L sorafenib for 48 h showed 
high sensitivity to NK cells. Finally, NKG2D, an engineered NK-cell-activating receptor, was 
tested in vitro and in mice. All of the outcomes were positive in increasing the cytotoxicity of 
NK cells, providing the possibility of further clinical trials in HCC.
4.3.1.4. CAR-T cell
Chimeric antigen receptor redirected-T cells (CAR-T cells) are genetically modified T lympho-
cytes that specifically target tumor-associated antigens (TAAs) and kill cancer cells in an MHC-
independent manner [68, 69]. CAR-T cells have achieved inspiring outcomes in patients with 
B cell malignancies with great therapeutic efficacy in leukemia and lymphoma therapy. CAR 
T therapy is being studied for solid tumors, such as HCC [70]. In some solid tumors with a 
tremendous phenotypic heterogeneity, CAR T cells could target the tumor antigen and cause 
antigen-positive cell death, while antigen-negative cancer cells may induce tumor relapse. 
However, Cart T cell structure engineering has been evolved significantly. Recently, CAR T cells 
with a transgenic “payload or TRUCK,” also called the “fourth generation” CAR T cells, were 
designed [71]. This CAR T cells work by releasing inducible cytokines such as IL-12 which will 
augment T cell activation and further activate innate immune system to kill antigen negative 
cancer cells. Specific Tumor-associated antigens in HCC that recognized by cytotoxic T lym-
phocytes (CTLs) have been investigated. GPC3, which usually correlates with poor prognosis 
in HCC, has been demonstrated as a promising liver cancer-specific target in multiple studies, 
due to its overexpression in HCC and limited expression in normal tissues [72] GPC3-targeted 
CAR T cells could providing promising therapeutic intervention for GPC3-positive HCC. The 
ability of GPC3-targeted CAR T cells to eliminate GPC3-positive HCC cells was confirmed both 
in vivo and in vitro, and the survival of mice with HCC xenografts was prolonged with CAR T 
cell therapy in vivo [73]. In another study, T cells with two complementary CARs against GPC3 
and asialoglycoprotein receptor 1 (ASGR1) decreased the risk of on-target, off tumor toxicities 
and demonstrated potent antitumor immune responses targeting GPC3+ ASGR1+ HCCs both 
in vivo and in vitro [74]. However, to date, the related studies conducted have been predomi-
nantly basic, and more clinical trials are required to prove the efficacy of CAR T in HCC.
4.4. Combination strategies
Combination therapies include combinations of different checkpoint inhibitors with TKIs, 
oncolytic viruses, small molecules and ablative therapies.
Combining anti-PD-1 with sorafenib has been studied in an animal model in HCC. The results 
showed efficacy only with the concomitant targeting of the hypoxic and immunosuppres-
sive microenvironment with agents such as CXCR4 inhibitors, and not when combined with 
sorafenib alone [75]. According to these results, a potential future approach could be by care-
ful titration of VEGF inhibition with the aim to block the VEGF pathway and contemporarily 
alleviate hypoxia by vascular normalization, enhancing immunotherapy efficacy [76].
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Checkpoint inhibitors combinations have also been studied, as a way to improve synergy and 
overcome resistance. PD-L1 is not the only immunosuppressive factor in the tumor micro-
environment. The regulatory T cells (Treg) stands out among the immunosuppressive cells 
of the tumor microenvironment. Anti-CTLA-4 agents deplete tumor-associated Treg via an 
FccR dependant mechanism in preclinical models and have promising result in malignant 
melanoma [77].
5. Cytotoxic chemotherapies
Historically, traditional chemotherapeutic agents have not shown great efficacy in the treat-
ment of HCC when used in the advanced disease stage, in particular in case of progression 
after locoregional therapy. Moreover, conventional cytotoxic chemotherapies have not pro-
vided a clinical benefit or prolonged survival for patients with advanced HCC. There are 
limited data supporting the use of cytotoxic chemotherapies in unresectable disease, and it 
should be used preferably in the context of a clinical trial [78].
6. Conclusions
Advanced HCC remains a deadly disease with limited systemic treatment options. The 
advent of sorafenib as first-line treatment ignited a plethora of trials testing various targeted 
and immunotherapeutic approaches. Currently, both regorafenib and nivolumab are FDA 
approved for second-line treatment among patients with advanced HCC who progressed 
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Yes First line SHARP OS, PFS [3]
Lenvatinib MKI VEGFR, 
FGFR, 
PDGFRs, c-kit
No First line REFLECT Non-inferior 
to sorafenib
[11]
Regorafenib MKI VEGFR, anti-
stromal TKI
Yes Second line RESORCE OS, DCR [13]
Cabozantinib MKI VEGFR, MET, 
AXL c-KIT





Anti-PD-1 Yes Second line CheckMate-040 DCR, OS,PFS [36]
List of abbreviations: MOA: mechanism of action, Ref: references, DCR: disease control rate, FGFR: fibroblast growth 
factor receptor, McA: monoclonal antibody, MKI: multi-tyrosine kinase inhibitor, OS: overall survival, PFS: progression 
free survival, PDGFR: platelet-derived growth factor receptor, PD-1: programmed death-1, TKI: trosine kinase inhibitor, 
VEGFRs: vascular endothelial growth factor receptors.
Table 1. Most common systemic agents for advanced HCC.
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on sorafenib. The list of available treatment options (Table 1) is expected to increase with 
the encouraging results of several ongoing early phase trials, which eventually will lead to 
improvement in patients survivals.
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